Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 7 W ELECTROLYTES versus HEPATASOL 8.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 7 W ELECTROLYTES versus HEPATASOL 8.
AMINOSYN 7% W/ ELECTROLYTES vs HEPATASOL 8%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amino acids are the building blocks for protein synthesis in the body. This solution provides essential and non-essential amino acids to maintain nitrogen balance and support tissue repair and growth when oral intake is inadequate.
HEPATASOL 8% (amino acid injection) provides essential and non-essential amino acids to support protein synthesis and correct nitrogen balance in hepatic encephalopathy. It reduces plasma ammonia levels by promoting urea cycle activity and decreasing aromatic amino acids.
Intravenous infusion at 1-1.5 g amino acids/kg/day. Typical adult dose: 500 mL of 7% solution (35 g amino acids) infused over 8-12 hours, repeated daily as per nitrogen requirements.
Intravenous infusion of 500 mL (40 g amino acids) over 3-4 hours, administered once daily or as directed by clinical response.
None Documented
None Documented
Terminal elimination half-life for the constituent amino acids ranges from 0.5 to 4 hours, depending on the specific amino acid and metabolic state. Clinically, infusion rate should be adjusted to avoid accumulation in renal impairment.
Approximately 30-60 minutes for individual amino acids; clinical context: rapid clearance supports continuous infusion to maintain plasma levels.
Primarily renal. Amino acids are deaminated, and nitrogen is excreted as urea in urine. Biliary/fecal excretion is negligible. Almost 100% of infused amino acids are either metabolized or excreted as urea and other nitrogenous wastes.
Renal: >95% of administered amino acids are reabsorbed and metabolized; negligible unchanged excretion. Biliary/fecal: <5%
Category C
Category C
Amino Acid Solution
Amino Acid Solution